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Concordance Between Electronic Health Record Data
andMedicare Part D Claims Data for Oral Anticancer Drug Use
Manvi Sharma, RPh, MBA, MS, PhD; Michael L. Johnson, PhD; Hui Zhao, PhD; Sharon H. Giordano, MD, MPH, FASCO; Holly M. Holmes, MD, MS, AGSF
Introduction
Real-world evidence from electronic health records (EHRs) and claims data are being evaluated for
use in regulatory decision-making.1,2 The objective of our study was to determine the concordance
between EHR and Medicare Part D (MPD) claims data for the receipt of oral anticancer agents, a
rapidly growing treatment option for cancer.
Methods
In this cross-sectional study, MPD claims were linked with EHRs for patients treated at The University
of TexasMDAnderson Cancer Center (MDACC) via the Texas Cancer registry. The institutional review
boards of The University of Texas MDACC, the Texas Cancer Registry, and the Centers for Medicare
&Medicaid Services approved this study. Informed consent was waived because this study described
all data in aggregate form, without the identification of any individual participants, and involved no
more thanminimal risk to participants. Furthermore, the waiver would not adversely affect the rights
and welfare of the participants, and the research could not be carried out without the waiver. This
study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
reporting guideline for cross-sectional studies.
Patients were aged 65 years and older; had breast, prostate, kidney, or colon cancer or chronic
myeloid leukemia; andwere enrolled inMPD during treatment atMDACC between January 2007 and
December 2012. Use of any oral anticancer agent was extracted from theMDACC EHR through
retrospective medical record review of reconciled medication lists, pharmacy records, and clinic
notes (eFigure in the Supplement). The EHR did not have computerized order entry, and thus, the
data reflect medication reconciliation, indicating potential use of a medication. Event files in MPD
claims data were searched to identify claims for any oral anticancer drug for each patient and to
reflect prescriptions that were actually dispensed to patients.
Data analysis was conducted fromNovember 2017 to April 2019, in SAS Enterprise Guide 6.1
(SAS Institute). We ascertained EHR andMPD concordance rates with κ statistics after matching drug
name and requiring overlapping treatment dates. No prespecified level of significance was set.
Results
The study sample consisted of 208 EHRmedication records and 250MPD claims for 170 patients.
Patients had a median (interquartile range) age of 69 (65-73) years, and 106 (62.4%) were men.
There were 22 different oral anticancer drugs evaluated (Box). Bicalutamide (74 records [29.6%] in
MPD, 54 records [25.9%] in EHR), anastrozole (36 [14.4%] in MPD, 34 [16.3%] in EHR), and
pazopanib (25 [10.0%] in MPD, 18 [8.6%] in EHR) were themost frequently used drugs. The overall
percentage agreement between the 2 data sets was 73.8%, inwhich 176 events were yes in both data
sets and 123 eventswere no in both data sets. The percentage disagreementwas 26.2%, inwhich 74
MPD claims (18.3%) were not found in the EHR, and 32 EHR drugs (7.9%) were not found in theMPD
(κ = 0.47; 95% CI, 0.39-0.56) (Table).
Box. List of Oral Anticancer Drugs
Assessed for Use
1. Abiraterone
2. Anastrozole
3. Axitinib
4. Bicalutamide
5. Dasatinib
6. Diethyl Stilbestrol
7. Enzalutamide
8. Erlotinib
9. Estramustine
10. Everolimus
11. Exemestane
12. Flutamide
13. Hydroxyurea
14. Imatinib
15. Letrozole
16. Nilotinib
17. Nilutamide
18. Pazopanib
19. Sorafenib
20. Sunitinib
21. Tamoxifen
22. Thalidomide
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Discussion
Themoderate rate of agreement (ie, 73.8%) found in this studymay be because of various reasons.
The EHR may be missing oral anticancer use for patients receiving only a consultation or because of
incompletemedication reconciliation ormedical record information. Claims inMPDmay bemissing
because patients could obtain medications by other means that do not result in an MPD claim,
including discount or other assistance programs. Du et al3 reported a 96% rate of agreement with a
κ of 0.72 (95% CI, 0.64-0.79) between a tumor registry and medical records for tamoxifen or
aromatase-inhibitors for breast cancer. Lund et al4 reported 55% sensitivity and 47% specificity of
Medicare claims to identify the use of capecitabine when compared with data from the National
Cancer Institute Patterns of Care study. However, to our knowledge, our study was the first to
compare MPD claims with EHR data for use of oral anticancer agents. A potential limitation of this
study is that it was a single site study, thus the results may not be generalizable to all MPD claims.
This study provides an estimate of the potential information difference that may be present
when EHR or claims data alone are used, with important implications for studies of oral anticancer
drug use patterns, drug spending, outcomes, and quality measures. For the drugs that are in the EHR
but are missing fromMPD (8%), there is concern regarding how to fully evaluate the use of costly
anticancer drugs using MPD data.2,5 For the drugs that are in theMPD but are missing in EHR (18%),
there is concern regarding the completeness of utilization patterns that are generated based
on EHR.6
A data linkage between EHR and administrative claims would potentially improve the capture
of exposures and outcomes and thus produce better quality data that could be used in regulatory
decision-making.
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